252 related articles for article (PubMed ID: 27770561)
61. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs.
Llaneras J; Riveiro-Barciela M; Lens S; Diago M; Cachero A; García-Samaniego J; Conde I; Arencibia A; Arenas J; Gea F; Torras X; Luis Calleja J; Antonio Carrión J; Fernández I; María Morillas R; Rosales JM; Carmona I; Fernández-Rodríguez C; Hernández-Guerra M; Llerena S; Bernal V; Turnes J; González-Santiago JM; Montoliu S; Figueruela B; Badia E; Delgado M; Fernández-Bermejo M; Iñarrairaegui M; Pascasio JM; Esteban R; Mariño Z; Buti M
J Hepatol; 2019 Oct; 71(4):666-672. PubMed ID: 31203153
[TBL] [Abstract][Full Text] [Related]
62. Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in direct-acting antiviral-experienced patients with genotype 1 hepatitis C virus.
Lawitz E; Poordad F; Wells J; Hyland RH; Yang Y; Dvory-Sobol H; Stamm LM; Brainard DM; McHutchison JG; Landaverde C; Gutierrez J
Hepatology; 2017 Jun; 65(6):1803-1809. PubMed ID: 28220512
[TBL] [Abstract][Full Text] [Related]
63. Prevalence of resistance associated substitutions and efficacy of baseline resistance-guided chronic hepatitis C treatment in Spain from the GEHEP-004 cohort.
Pérez AB; Chueca N; Macías J; Pineda JA; Salmerón J; Rivero-Juárez A; Hidalgo-Tenorio C; Espinosa MD; Téllez F; Von-Wichmann MÁ; Omar M; Santos J; Hernández-Quero J; Antón JJ; Collado A; Lozano AB; García-Deltoro M; Casado M; Pascasio JM; Selfa A; Rosales JM; De la Iglesia A; Arenas JI; García-Bujalance S; Ríos MJ; Bernal E; Martínez O; García-Herola A; Vélez M; Rincón P; García F
PLoS One; 2019; 14(8):e0221231. PubMed ID: 31469856
[TBL] [Abstract][Full Text] [Related]
64. Phase 3, Multicenter Open-Label study to investigate the efficacy of elbasvir and grazoprevir fixed-dose combination for 8 weeks in treatment-naïve, HCV GT1b-infected patients, with non-severe fibrosis.
Abergel A; Asselah T; Mallat A; Chanteranne B; Faure F; Larrey D; Gournay J; Loustaud-Ratti V; Di Martino V; Fouchard-Hubert I; Pol S; Bailly F; Samuel D; Tran A; Dodel M; Andant N; Lamblin G; Muti L; Reymond M; Teilhet C; Pereira B; Buchard B
Liver Int; 2020 Aug; 40(8):1853-1859. PubMed ID: 32383275
[TBL] [Abstract][Full Text] [Related]
65. Regulatory Analysis of Effects of Hepatitis C Virus NS5A Polymorphisms on Efficacy of Elbasvir and Grazoprevir.
Komatsu TE; Boyd S; Sherwat A; Tracy L; Naeger LK; O'Rear JJ; Harrington PR
Gastroenterology; 2017 Feb; 152(3):586-597. PubMed ID: 27773808
[TBL] [Abstract][Full Text] [Related]
66. Projected impact of elbasvir/grazoprevir in patients with hepatitis C virus genotype 1 and chronic kidney disease in Vietnam.
Nwankwo C; Corman SL; Elbasha EH
J Infect Public Health; 2019; 12(4):502-508. PubMed ID: 30711348
[TBL] [Abstract][Full Text] [Related]
67. Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial.
Waked I; Shiha G; Qaqish RB; Esmat G; Yosry A; Hassany M; Soliman R; Mohey MA; Allam N; Zayed N; Asselah T; Hall C; Redman R; Mobashery N; Doss W
Lancet Gastroenterol Hepatol; 2016 Sep; 1(1):36-44. PubMed ID: 28404110
[TBL] [Abstract][Full Text] [Related]
68. Effectiveness of current and future regimens for treating genotype 3 hepatitis C virus infection: a large-scale systematic review.
Fathi H; Clark A; Hill NR; Dusheiko G
BMC Infect Dis; 2017 Nov; 17(1):722. PubMed ID: 29145802
[TBL] [Abstract][Full Text] [Related]
69. An Open-Label, Randomized, Active-Controlled Trial of 8 Versus 12 Weeks of Elbasvir/Grazoprevir for Treatment-Naive Patients With Chronic Hepatitis C Genotype 1b Infection and Mild Fibrosis (EGALITE Study): Impact of Baseline Viral Loads and NS5A Resistance-Associated Substitutions.
Huang CF; Hung CH; Cheng PN; Bair MJ; Huang YH; Kao JH; Hsu SJ; Lee PL; Chen JJ; Chien RN; Peng CY; Lin CY; Hsieh TY; Cheng CH; Dai CY; Huang JF; Chuang WL; Yu ML
J Infect Dis; 2019 Jul; 220(4):557-566. PubMed ID: 30957170
[TBL] [Abstract][Full Text] [Related]
70. Identification of microRNA associated with the elimination of hepatitis C virus genotype 1b by direct-acting antiviral therapies.
Yoneyama H; Morishita A; Iwama H; Fujita K; Masaki T; Tani J; Tadokoro T; Nomura T; Sakamoto T; Oura K; Takuma K; Nakahara M; Mimura S; Deguchi A; Oryu M; Tsutsui K; Himoto T; Shimotohno K; Wakita T; Kobara H; Masaki T
J Gastroenterol Hepatol; 2021 Apr; 36(4):1126-1135. PubMed ID: 32839985
[TBL] [Abstract][Full Text] [Related]
71. High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis.
Gane E; Poordad F; Wang S; Asatryan A; Kwo PY; Lalezari J; Wyles DL; Hassanein T; Aguilar H; Maliakkal B; Liu R; Lin CW; Ng TI; Kort J; Mensa FJ
Gastroenterology; 2016 Oct; 151(4):651-659.e1. PubMed ID: 27456384
[TBL] [Abstract][Full Text] [Related]
72. Transplanting hepatitis C virus-infected hearts into uninfected recipients: A single-arm trial.
McLean RC; Reese PP; Acker M; Atluri P; Bermudez C; Goldberg LR; Abt PL; Blumberg EA; Van Deerlin VM; Reddy KR; Bloom RD; Hasz R; Suplee L; Sicilia A; Woodards A; Zahid MN; Bar KJ; Porrett P; Levine MH; Hornsby N; Gentile C; Smith J; Goldberg DS
Am J Transplant; 2019 Sep; 19(9):2533-2542. PubMed ID: 30768838
[TBL] [Abstract][Full Text] [Related]
73. Treatment of hepatitis C virus infection in people with opioid use disorder: a real-world study of elbasvir/grazoprevir in a US Department of Veterans Affairs population.
Kramer JR; Puenpatom A; Cao Y; Yu X; El-Serag HB; Kanwal F
Am J Drug Alcohol Abuse; 2022 Jul; 48(4):445-453. PubMed ID: 35077656
[No Abstract] [Full Text] [Related]
74. Elbasvir/Grazoprevir: First Global Approval.
Keating GM
Drugs; 2016 Apr; 76(5):617-24. PubMed ID: 26943930
[TBL] [Abstract][Full Text] [Related]
75. A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients.
Duerr M; Schrezenmeier EV; Lehner LJ; Bergfeld L; Glander P; Marticorena Garcia SR; Althoff CE; Sack I; Brakemeier S; Eckardt KU; Budde K; Halleck F
BMC Nephrol; 2019 Feb; 20(1):36. PubMed ID: 30717681
[TBL] [Abstract][Full Text] [Related]
76. Efficacy and safety of elbasvir/grazoprevir for 8 or 12 weeks for hepatitis C virus genotype 4 infection: A randomized study.
Asselah T; Pol S; Hezode C; Loustaud-Ratti V; Leroy V; Ahmed SNS; Ozenne V; Bronowicki JP; Larrey D; Tran A; Alric L; Nguyen-Khac E; Robertson MN; Hanna GJ; Brown D; Asante-Appiah E; Su FH; Hwang P; Hall JD; Guidoum A; Hagen K; Haber BA; Talwani R; Serfaty L
Liver Int; 2020 May; 40(5):1042-1051. PubMed ID: 31765046
[TBL] [Abstract][Full Text] [Related]
77. Spotlight on grazoprevir-elbasvir once-daily combination and its potential in the treatment of hepatitis C.
Suraweera D; Weeratunga AN; Saab S
Drug Des Devel Ther; 2016; 10():2119-27. PubMed ID: 27418810
[TBL] [Abstract][Full Text] [Related]
78. Elbasvir and grazoprevir for the treatment of hepatitis C.
Wang SJ; Huang CF; Yu ML
Expert Rev Anti Infect Ther; 2021 Sep; 19(9):1071-1081. PubMed ID: 33428488
[No Abstract] [Full Text] [Related]
79. High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world.
Pérez AB; Chueca N; García-Deltoro M; Martínez-Sapiña AM; Lara-Pérez MM; García-Bujalance S; Aldámiz-Echevarría T; Vera-Méndez FJ; Pineda JA; Casado M; Pascasio JM; Salmerón J; Alados-Arboledas JC; Poyato A; Téllez F; Rivero-Juárez A; Merino D; Vivancos-Gallego MJ; Rosales-Zábal JM; García F;
J Hepatol; 2019 Nov; 71(5):876-888. PubMed ID: 31279901
[TBL] [Abstract][Full Text] [Related]
80. Elbasvir/grazoprevir is effective and tolerable for the treatment of HCV GT1-infected patients: A real world multicenter observatory study in Taiwan.
Cheng PN; Chen CY; Yu ML; Lin CC; Lin CY; Peng CY; Tseng KC; Lo CC; Tseng IH; Liu CJ
J Microbiol Immunol Infect; 2021 Aug; 54(4):588-595. PubMed ID: 32499107
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
